Stay updated with breaking news from Ultibro Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +5% (cc1, +1% USD), core operating income grew +9% (cc, +3% USD) Innovative Medicines (IM) sales grew +4% (cc, +1% USD) and core operating
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
Novartis Pharma AG: Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged. Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Oncology BU grew +7% (cc, +11% USD) driven by Promacta/Revolade (+18% cc), Sandoz grew +5% (cc, +11% USD) as the business is starting to stabilize Excluding prior year forward purchasing de-stocking, we estimate Q2 net sales grew +5% (cc, +10% USD), Innovative Medicines grew +7% (cc, +11% USD) and Sandoz declined -1% (cc...